Prostaglandin EP2 receptor: Novel therapeutic target for human cancers (Review)

42Citations
Citations of this article
60Readers
Mendeley users who have this article in their library.

Abstract

Prostaglandin E2 (PGE2) receptor 2 subtype (EP2), which is a metabolite of arachidonic acid that binds with and regulates cellular responses to PGE2, is associated with numerous physiological and pathological events in a wide range of tissues. As a stimulatory G protein-coupled receptor, PGE2-induced EP2 activation can activate adenylate cyclase, leading to increased cytoplasmic cAMP levels and activation of protein kinase A. The EP2 receptor can also activate the glycogen synthase kinase 3β and β-catenin pathways. The present study aimed to review the roles of the EP2 receptor in tumor development, including immunity, chronic inflammation, angiogenesis, metastasis and multidrug resistance. Furthermore, the involvement of the EP2 receptor signaling pathway in cancer was discussed. Understanding the role and mechanisms of action of the EP2 receptor, and its importance in targeted therapy, may help identify novel methods to improve management of numerous types of cancer.

Cite

CITATION STYLE

APA

Sun, X., & Li, Q. (2018, September 1). Prostaglandin EP2 receptor: Novel therapeutic target for human cancers (Review). International Journal of Molecular Medicine. Spandidos Publications. https://doi.org/10.3892/ijmm.2018.3744

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free